Paratek Pharmaceuticals Inc. (PRTK)

10.9 -0.2 (-1.802%)

IEX Real-Time Price

May 22, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 11.1

Price Open 11.05

Volume: 419,037

Avg Volume: 782,133

Market Cap: 344.4M

P/E Ratio -3.52

52 Wk Range 10.1-29



PRTK Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-04-30
30.33M
4.05M
5.07
13.35%

2018-04-13
30.17M
2.5M
6.11
8.29%

2018-03-29
30.17M
3.37M
8.54
11.16%

2018-03-15
30.42M
3.32M
8.71
10.92%




PRTK Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-09
Q1 2018
BTO
-0.94 (5)
-0.91
0.03

2018-05-03
Q1 2018
N/A
-0.95 (5)
0.00
0.00

2018-03-01
Q4 2017
N/A
-0.72 (4)
-0.78
-0.06

2017-11-08
Q3 2017
BTO
-0.93 (6)
-0.78
-0.06

News

Tracking Seth Klarman's Baupost Group Holdings - Q1 2018 Update (2018-05-15 10:33 SeekingAlpha)

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarmans regulatory 13F Form filed on 05/14/2018. Please visit our Tracking Seth Klarmans Baupost Group Holdings …

 

Achaogen: Explicating The Prospects Of C-Scape (2018-05-13 06:36 SeekingAlpha)

Long ago, Ben Graham taught me that Price is what you pay; value is what you get. Whether were talking about socks or stocks, I like buying quality merchandise when it is marked down. - Warren Buffett Achaogen (NASDAQ: AKAO ) is a stellar investment for opportun…

 

Paratek Pharmaceuticals' (PRTK) CEO Michael Bigham on Q1 2018 Results - Earnings Call Transcript (2018-05-09 12:10 SeekingAlpha)

Paratek Pharmaceuticals, Inc. (PRTK) Q1 2018 Earnings Conference Call May 9, 2018 08:30 AM ET Executives Michael Bigham - Chairman and CEO Doug Pagn - CFO Adam Woodrow - Chief Commercial Officer Evan Loh - President, COO and Chief Medical Officer Ben Strain - Executive …

 

Paratek up 1% on Q1 result (2018-05-09 08:54 SeekingAlpha)

Paratek Pharmaceuticals ( PRTK ) Q1 results : Revenues: $10K (-44.4%); Operating Loss: ($26.7M) (+0.4%); Net Loss: ($27.8M) (-0.4%); Loss Per Share: ($0.91) (+20.2%); Quick Assets: $184.3M (+21.5%). More news on: Paratek Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and com…

 

Paratek Pharmaceuticals EPS in-line (2018-05-09 07:33 SeekingAlpha)

Paratek Pharmaceuticals (NASDAQ: PRTK ): Q1 EPS of -$0.91 in-line. More news on: Paratek Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more …

 


Statistics

Shares Outstanding: 31.6M

Top 15 Institution Percent: 82.10

Price To Sales: 28.82

Price To Book: 3.28

Revenue: 7.53M

Gross Profit: N/A

Cash: 84.58M

Debt: N/A

Return On Assets: -52.65

Return On Equity: -91.17

Profit Margin: N/A

Price History

Beta: 0.58

50-day Moving Avg: 12.43

200-day Moving Avg: 18.02

YTD Change: -40.80

5-day Change: -6.72

1-month Change: 2.30

3-month Change: -17.78

6-month Change: -44.78

1-year Change: -48.01

Revenue Per Share: 0.00

Revenue Per Employee: 90675.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Paratek Pharmaceuticals Inc.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.paratekpharm.com

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics based upon tetracycline chemistry.